Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Giuliano Tocci, Francesco Paneni, Jasmine Passerini & Massimo Volpe. (2012) Triple combination therapy to improve blood pressure control: experience with olmesartan–amlodipine–hydrochlorothiazide therapy. Expert Opinion on Pharmacotherapy 13:18, pages 2687-2697.
Read now
Read now
Giuliano Tocci & Massimo Volpe. (2011) Fixed-combination therapy to improve blood pressure control: experience with olmesartan-based therapy. Expert Review of Cardiovascular Therapy 9:7, pages 829-840.
Read now
Read now
Carlos M Ferrario & Ronald D Smith. (2010) Role of olmesartan in combination therapy in blood pressure control and vascular function. Vascular Health and Risk Management 6, pages 701-709.
Read now
Read now
Joel M. Neutel, Stanley S. Franklin, Amitabha Bhaumik, Pablo Lapuerta & Suzanne Oparil. (2009) Safety and Tolerability of Fixed-Dose Irbesartan/Hydrochlorothiazide for Rapid Control of Severe Hypertension. Clinical and Experimental Hypertension 31:7, pages 572-584.
Read now
Read now
Mark Greathouse. (2008) Olmesartan medoxomil-based therapy for the management of hypertension. Expert Review of Clinical Pharmacology 1:5, pages 593-604.
Read now
Read now
Articles from other publishers (15)
Elena Filipova, Stela Dineva, Katya Uzunova, Velichka Pavlova, Krassimir Kalinov & Toni Vekov. (2020) Combining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide – which is the better alternative? A meta-analysis. Systematic Reviews 9:1.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
329
356
.
Samir G Mallat. (2012) What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?. Cardiovascular Diabetology 11:1, pages 32.
Crossref
Crossref
Steven G. Chrysant, Joel M. Neutel, Keith C. Ferdinand & for the Inclusive investigators. (2009) Irbesartan/Hydrochlorothiazide for the Treatment of Isolated Systolic Hypertension:A Subgroup Analysis of the INCLUSIVE Trial. Journal of the National Medical Association 101:4, pages 300-307.
Crossref
Crossref
Vipul P. Rane, Kiran R. Patil, Jaiprakash N. Sangshetti, Ravindra D. Yeole & Devanand B. Shinde. (2008) Stability-Indicating LC Method for the Determination of Olmesartan in Bulk Drug and in Pharmaceutical Dosage Form. Chromatographia 69:1-2, pages 169-173.
Crossref
Crossref
Andrew J. Lewin & Matthew R. Weir. (2008) Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: A post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial. Clinical Therapeutics 30:12, pages 2354-2365.
Crossref
Crossref
Elizabeth O. OfiliGreg CableJoel M. NeutelElijah Saunders. (2008) Efficacy and Safety of Fixed Combinations of Irbesartan/Hydrochlorothiazide in Hypertensive Women: The Inclusive Trial. Journal of Women's Health 17:6, pages 931-938.
Crossref
Crossref
Roberto Fogari, Annalisa Zoppi, Amedeo Mugellini, Paola Preti, Maurizio Destro, Andrea Rinaldi & Giuseppe Derosa. (2008) Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study. Current Therapeutic Research 69:1, pages 1-15.
Crossref
Crossref
Elijah Saunders, Greg Cable & Joel Neutel. (2008) Predictors of Blood Pressure Response to Angiotensin Receptor Blocker/Diuretic Combination Therapy: A Secondary Analysis of the Irbesartan/Hydrochlorothiazide Blood Pressure Reductions in Diverse Patient Populations (INCLUSIVE) Study. The Journal of Clinical Hypertension 10:1, pages 27-33.
Crossref
Crossref
Matthew R. Weir, Joel M. Neutel, Amitabha Bhaumik, Maria Elena De Obaldia & Pablo Lapuerta. (2007) The Efficacy and Safety of Initial Use of Irbesartan/Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Patients With and Without High Cardiovascular Risk. The Journal of Clinical Hypertension 9:s12, pages 23-30.
Crossref
Crossref
S G Chrysant, B Dimas & M Shiraz. (2007) Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update. Journal of Human Hypertension 21:9, pages 699-708.
Crossref
Crossref
Vivencio Barrios, Alessandro Boccanelli, Silke Ewald, Xavier Girerd, Anthony Heagerty, Jean-Marie Krzesinski, Robert Lins, Jos?? Rodicio, Thomas Stefenelli, Arend Woittiez & Michael B??hm. (2007) Efficacy and Tolerability of Olmesartan Medoxomil in Patients??with Mild to Moderate Essential Hypertension. Clinical Drug Investigation 27:8, pages 545-558.
Crossref
Crossref
R. Fogari, A. Zoppi, A. Mugellini, P. Preti, M. Destro, A. Rinaldi & G. Derosa. (2006) Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Advances in Therapy 23:5, pages 680-695.
Crossref
Crossref
Steven G. Chrysant & George S. Chrysant. (2006) The Pleiotropic Effects of Angiotensin Receptor Blockers. The Journal of Clinical Hypertension 8:4, pages 261-268.
Crossref
Crossref
Joel M. Neutel, Elijah Saunders, George L. Bakris, William C. Cushman, Keith C. Ferdinand, Elizabeth O. Ofili, James R. Sowers & Michael A. Weber. (2005) The Efficacy and Safety of Low- and High- Dose Fixed Combinations of Irbesartan/Hydrochlorothiazide in Patients With Uncontrolled Systolic Blood Pressure on Monotherapy: The INCLUSIVE Trial. The Journal of Clinical Hypertension 7:10, pages 578-586.
Crossref
Crossref